

DENTSPLY SIRONA Inc.

Form 10-Q

May 03, 2019

DENTSPLY SIRONA Inc.Large Accelerated

FilerFALSEFALSE10-QXRAY2019Q1FALSE0000818479--12-31March 31,

20191.001.000.250.25——0.010.01400400264.5264.5223.8223.040.741.50.08750.0875P5YP10Yxbrli:shares0000818479201

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 10-Q**

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

**For the quarterly period ended March 31, 2019**

Commission File Number 0-16211

**DENTSPLY SIRONA Inc.**

(Exact name of registrant as specified in its charter)

Delaware 39-1434669

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer

Identification No.)

221 West Philadelphia Street, York, PA 17401-2991

(Address of principal executive offices) (Zip Code)

(717) 845-7511  
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$.01 per share	XRAY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was

Edgar Filing: DENTSPLY SIRONA Inc. - Form 10-Q

required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer <input checked="" type="checkbox"/>	Accelerated filer <input type="checkbox"/>
Non-accelerated filer <input type="checkbox"/>	Smaller reporting company <input type="checkbox"/>
	Emerging growth company <input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  
Yes  No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: At April 26, 2019, DENTSPLY SIRONA Inc. had 233,977,496 shares of Common Stock outstanding.

---

**DENTSPLY SIRONA Inc.****TABLE OF CONTENTS**

<b><u>PART I</u></b>	<b><u>FINANCIAL INFORMATION</u></b>	<b><u>Page</u></b>
<u>Item 1</u>	<u>Financial Statements (unaudited)</u>	<u>3</u>
	<u>Consolidated Statements of Operations</u>	<u>3</u>
	<u>Consolidated Statements of Comprehensive Income (Loss)</u>	<u>4</u>
	<u>Consolidated Balance Sheets</u>	<u>5</u>
	<u>Consolidated Statements of Changes in Equity</u>	<u>6</u>
	<u>Consolidated Statements of Cash Flows</u>	<u>7</u>
	<u>Notes to Unaudited Interim Consolidated Financial Statements</u>	<u>8</u>
<u>Item 2</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>35</u>
<u>Item 3</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	<u>49</u>
<u>Item 4</u>	<u>Controls and Procedures</u>	<u>49</u>
<b><u>PART II</u></b>	<b><u>OTHER INFORMATION</u></b>	

<u>Item 1</u>	<u>Legal Proceedings</u>	<u>50</u>
<u>Item 1A</u>	<u>Risk Factors</u>	<u>50</u>
<u>Item 2</u>	<u>Unregistered Sales of Securities and Use of Proceeds</u>	<u>50</u>
<u>Item 6</u>	<u>Exhibits</u>	<u>51</u>
<u>Signatures</u>		<u>52</u>

**PART I – FINANCIAL INFORMATION****Item 1 – Financial Statements****DENTSPLY SIRONA INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF OPERATIONS**

(in millions, except per share amounts)

(unaudited)

	Three Months Ended March	
	31,	
	2019	2018
Net sales	\$ 946.2	\$ 956.1
Cost of products sold	446.5	442.0
Gross profit	499.7	514.1
Selling, general and administrative expenses	431.9	435.2
Restructuring and other costs	20.5	10.2
Operating income	47.3	68.7
Other income and expenses:		
Interest expense	8.4	8.6
Interest income	(1.1)	(0.6)
Other expense (income), net	(13.8)	(34.1)
Income before income taxes	53.8	94.8
Provision for income taxes	14.6	13.7
Net income	39.2	81.1
Less: Net loss attributable to noncontrolling interest	—	(0.1)
Net income attributable to Dentsply Sirona	\$ 39.2	\$ 81.2

Net income per  
common share  
attributable to  
Dentsply Sirona:

Basic	\$ 0.18	\$ 0.36
Diluted	\$ 0.17	\$ 0.35

Weighted  
average  
common shares  
outstanding:

Basic	223.3	227.2
Diluted	225.0	229.9

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

3

---

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

(in millions)

(unaudited)

	Three Months Ended March	
	31,	
	2019	2018
Net income	\$ 39.2	\$ 81.1
Other comprehensive (loss) income, net of tax		
Foreign currency translation (loss) gain	(61.0)	65.7
Net gain (loss) on derivative financial instruments	1.7	(12.0)
Net realized holding gain on available for sale securities	—	(44.3)
Pension liability gain	0.9	1.2
Total other comprehensive (loss) income, net of tax	(58.4)	10.6
Total comprehensive (loss) income	(19.2)	91.7
Less:		
Comprehensive income attributable to noncontrolling interests	0.3	0.5
Total comprehensive (loss) income attributable to Dentsply Sirona	\$ (19.5)	\$ 91.2

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

4

---

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS**

(in millions, except per share amounts)  
(unaudited)

	March 31, 2019	December 31, 2018
<b>Assets</b>		
Current Assets:		
Cash and cash equivalents	\$ 225.4	\$ 309.6
Accounts and notes receivables-trade, net	658.5	701.9
Inventories, net	618.2	598.9
Prepaid expenses and other current assets	293.5	277.6
Total Current Assets	1,795.6	1,888.0
Property, plant and equipment, net	853.9	870.6
Operating lease right-of-use assets, net	163.9	—
Identifiable intangible assets, net	2,324.7	2,420.3
Goodwill, net	3,399.2	3,431.3
Other noncurrent assets, net	67.2	76.8
Total Assets	\$ 8,604.5	\$ 8,687.0
<b>Liabilities and Equity</b>		
Current Liabilities:		
Accounts payable	\$ 269.0	\$ 283.9
Accrued liabilities	511.1	578.9
Income taxes payable	69.8	58.1
Notes payable and current portion of long-term debt	20.7	92.4
Total Current Liabilities	870.6	1,013.3
Long-term debt	1,545.1	1,564.9

Operating lease liabilities	125.5	—
Deferred income taxes	535.1	552.8
Other noncurrent liabilities	418.7	423.0
Total Liabilities	3,495.0	3,554.0
Commitments and contingencies	—	—
Equity:		
Preferred stock, \$1.00 par value; 0.25 million shares authorized; no shares issued	—	—
Common stock, \$0.01 par value; 400.0 million shares authorized and 264.5 million shares issued at March 31, 2019 and December 31, 2018, respectively	2.6	2.6
223.8 million and 223.0 million shares outstanding at March 31, 2019 and December 31, 2018, respectively		
Capital in excess of par value	6,520.4	6,522.3
Retained earnings	1,245.0	1,225.9
Accumulated other comprehensive loss	(537.4)	(478.7)
Treasury stock, at cost, 40.7 million and 41.5 million shares at March 31, 2019 and December 31, 2018, respectively	(2,122.9)	(2,151.0)
Total Dentsply Sirona Equity	5,107.7	5,121.1
Noncontrolling interests	1.8	11.9

Edgar Filing: DENTSPLY SIRONA Inc. - Form 10-Q

Total Equity	5,109.5		5,133.0	
Total Liabilities and Equity	\$	8,604.5	\$	8,687.0

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

5

---

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**

(in millions)

(unaudited)

	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Total Dentsply Sirona Equity	Noncontrolling Interests	Total Equity
<b>Balance at December 31, 2018</b>	\$ 2.6	\$ 6,522.3	\$ 1,225.9	\$ (478.7)	\$ (2,151.0)	\$ 5,121.1	\$ 11.9	\$ 5,133.0
Net income	—	—	39.2	—	—	39.2	—	39.2
Other comprehensive— loss	—	—	—	(58.7)	—	(58.7)	0.3	(58.4)
Divestiture of noncontrolling interest	—	—	—	—	—	—	(10.4)	(10.4)
Exercise of stock options	—	1.5	—	—	18.2	19.7	—	19.7
Stock based compensation— expense	—	9.1	—	—	—	9.1	—	9.1
Funding of Employee Stock Purchase Plan	—	0.1	—	—	1.9	2.0	—	2.0
Restricted Stock Unit "RSU" distributions	—	(12.8)	—	—	8.0	(4.8)	—	(4.8)
RSU dividends	—	0.2	(0.2)	—	—	—	—	—
Cash dividends (\$0.0875 per share)	—	—	(19.9)	—	—	(19.9)	—	(19.9)
<b>Balance at March 31, 2019</b>	\$ 2.6	\$ 6,520.4	\$ 1,245.0	\$ (537.4)	\$ (2,122.9)	\$ 5,107.7	\$ 1.8	\$ 5,109.5

	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Total Dentsply Sirona Equity	Noncontrolling Interests	Total Equity
<b>Balance at December</b>	\$ 2.6	\$ 6,543.9	\$ 2,316.2	\$ (291.0)	\$ (1,955.4)	\$ 6,616.3	\$ 11.6	\$ 6,627.9

Edgar Filing: DENTSPLY SIRONA Inc. - Form 10-Q

**31, 2017**

Net income	—	—	81.2	—	—	81.2	(0.1)	81.1
Other comprehensive income	—	—	—	10.0	—	10.0	0.6	10.6
Exercise of stock options	(1.8)	—	—	—	9.4	7.6	—	7.6
Cumulative effect on adoption of ASC 606	—	—	(6.0)	—	—	(6.0)	—	(6.0)
Reclassification on adoption of ASU No. 2016-16	—	—	(2.7)	—	—	(2.7)	—	(2.7)
Reclassification on adoption of ASU No. 2018-02	—	—	7.6	—	—	7.6	—	7.6
Stock based compensation expense	9.3	—	—	—	—	9.3	—	9.3
RSU distributions	(19.9)	—	—	—	9.9	(10.0)	—	(10.0)
RSU dividends	0.2	(0.2)	—	—	—	—	—	—
Cash dividends (\$0.875 per share)	—	—	(20.2)	—	—	(20.2)	—	(20.2)
<b>Balance at March 31, 2018</b>	\$ 2.6	\$ 6,531.7	\$ 2,375.9	\$ (281.0)	\$ (1,936.1)	\$ 6,693.1	\$ 12.1	\$ 6,705.2

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

(in millions)  
(unaudited)

	Three Months Ended March	
	31,	
	2019	2018
<b>Cash flows from operating activities:</b>		
Net income	\$ 39.2	\$ 81.1
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	34.9	33.3
Amortization of intangible assets	48.2	49.9
Amortization of deferred financing costs	0.7	0.7
Indefinite-lived intangible asset impairment	5.3	—
Deferred income taxes	(6.0)	(16.8)
Stock based compensation expense	9.2	9.3
Restructuring and other costs - non-cash	9.7	3.3
Other non-cash (income) expense	(7.8)	14.0
(Gain) loss on disposal of property, plant and equipment	(0.1)	0.5
Gain on divestiture of noncontrolling interest	(8.7)	—
Gain on sale of equity security	—	(44.1)
Changes in operating assets and liabilities, net of acquisitions:		
Accounts and notes receivable-trade, net	36.5	87.5
Inventories, net	(31.5)	(64.7)

Prepaid expenses and other current assets, net	(16.3)	(5.6)
Other noncurrent assets, net	4.8	(2.9)
Accounts payable	(11.3)	(3.9)
Accrued liabilities	(90.1)	(77.4)
Income taxes	12.3	(14.1)
Other noncurrent liabilities	0.3	5.0
<b>Net cash provided by operating activities</b>	<b>29.3</b>	<b>55.1</b>
<b>Cash flows from investing activities:</b>		
Capital expenditures	(33.9)	(35.8)
Cash paid for acquisitions of businesses and equity investments, net of cash acquired	—	(6.7)
Cash paid on sale of business or product line	(1.0)	—
Cash received on derivatives contracts	22.7	—
Cash paid on derivatives contracts	—	(2.4)
Expenditures for identifiable intangible assets	—	(3.3)
Purchase of short-term investments	(0.8)	—
Proceeds from sale of property, plant and equipment, net	0.3	3.0
<b>Net cash used in investing activities</b>	<b>(12.7)</b>	<b>(45.2)</b>
<b>Cash flows from financing activities:</b>		
Repayments on short-term borrowings	(67.9)	(7.8)
Cash dividends paid	(19.5)	(19.8)

Edgar Filing: DENTSPLY SIRONA Inc. - Form 10-Q

Proceeds from long-term borrowings, net of deferred financing costs	0.9	0.1
Repayments on long-term borrowings	(1.9)	(0.2)
Proceeds from exercised stock options	19.8	8.3
Cash paid for contingent consideration on prior acquisitions	(30.6)	—
<b>Net cash used in financing activities</b>	<b>(99.2)</b>	<b>(19.4)</b>
Effect of exchange rate changes on cash and cash equivalents	(1.6)	6.0
Net decrease in cash and cash equivalents	(84.2)	(3.5)
Cash and cash equivalents at beginning of period	309.6	320.6
Cash and cash equivalents at end of period	\$ 225.4	\$ 317.1

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

7

---

**DENTSPLY SIRONA Inc. and Subsidiaries**

**NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

**NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation**

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the U.S. Securities and Exchange Commission (“SEC”). The year-end consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by US GAAP. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and Subsidiaries (“Dentsply Sirona” or the “Company”) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company’s most recent Form 10-K for the year ended December 31, 2018.

The accounting policies of the Company, as applied in the interim consolidated financial statements presented herein are substantially the same as presented in the Company’s Form 10-K for the year ended December 31, 2018, except as may be indicated below.

**Revenue Recognition**

At March 31, 2019, the Company had \$28.7 million of deferred revenue recorded in Accrued liabilities in the Consolidated Balance Sheets. The Company expects to recognize significantly all of the deferred revenue within the next twelve months.

**Accounts and Notes Receivable**

The Company records a provision for doubtful accounts, which is included in Selling, general and administrative expenses in the Consolidated Statements of Operations.

Accounts and notes receivables – trade, net are stated net of allowances for doubtful accounts and trade discounts, which were \$32.5 million at March 31, 2019 and \$24.5 million at December 31, 2018.

**Recently Adopted Accounting Pronouncements**

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) with subsequent amendments (collectively, “Topic 842”). The Company adopted the new leasing standards on January 1, 2019 using the modified retrospective approach transition method. Results for reporting periods beginning after January 1, 2019 are presented under ASC 842, while prior periods are not adjusted and continue to be reported in accordance with historic accounting under ASC 840. The Company elected the package of practical expedients permitted under the transition guidance within the standard, which eliminates the reassessment of past leases, classification and initial direct costs. The Company did not elect to adopt the hindsight practical expedient. The Company recognized material right-of-use assets and liabilities in the Consolidated Balance Sheets for its operating lease commitments with terms greater than twelve months. See Note 8, Leases for additional information. The impact of adopting this standard, by financial statement line item, on January 1, 2019 was as follows:



(in millions)	Balance at January 1, 2019
Assets	
Operating lease right-of-use assets, net	167.1
Property, plant, and equipment, net	1.8
Liabilities	
Accrued liabilities	\$ 39.4
Notes	
payable and current portion of long-term debt	0.2
Long-term debt	1.5
Operating lease liabilities	126.5

In August 2017, the FASB issued ASU No. 2017-12, "Derivatives and Hedging." This newly issued accounting standard improves the financial reporting and disclosure of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The amendments in this update make improvements to simplify the application of the hedge accounting guidance in current US GAAP based on the feedback received from preparers, auditors, users and other stakeholders. More specifically, this update expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instruments and the hedged items in the financial statements. The effect of adoption should be reflected as of the beginning of the fiscal year of adoption. For cash flow and net investment hedges existing at the date of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate measurement of ineffectiveness to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year that an entity adopts the amendments in this update. The amended presentation and disclosure guidance is required only prospectively. The Company adopted this accounting standard during the quarter ended March 31, 2019. The adoption of this standard did not materially impact the statements of operations, financial position, cash flows and disclosures.

#### **Recently Issued Accounting Pronouncements Not Yet Adopted**

In August 2018, the FASB issued ASU No. 2018-14 "Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit

Plans." This newly issued accounting standard changes disclosure requirements for defined benefit plans, including removal and modification of existing disclosures. The amendments in this standard are required for fiscal years ending after December 15, 2020. Early adoption is permitted. The amendments should be applied on a retrospective basis for all periods presented. The Company is currently assessing the impact that this standard will have on its financial position, results of operations, cash flows and disclosures.

9

---

**NOTE 2 – STOCK COMPENSATION**

The following represents total stock based compensation expense for non-qualified stock options, RSUs and the tax related benefit for the three months ended March 31, 2019 and 2018:

(in millions)	Three Months Ended	
	2019	2018
Stock option expense	\$ 2.2	\$ 0.7
RSU expense	6.7	8.3
Total stock based compensation expense	\$ 8.9	\$ 9.0
Related deferred income tax benefit	\$ 1.4	\$ 1.8

For the three months ended March 31, 2019, stock compensation expense was \$8.9 million of which \$8.6 million was recorded in Selling, general, and administrative expense, and \$0.3 million was recorded in Cost of products sold in the Consolidated Statements of Operations.

For the three months ended March 31, 2018, stock compensation expense was \$9.0 million, of which \$7.0 million was recorded in Selling, general, and administrative expense, and \$0.3 million was recorded in Cost of products sold in the Consolidated Statements of Operations. For the three months ended March 31, 2018, the Company recorded \$1.7 million in Restructuring and other costs in the Consolidated Statements of Operations.

During the three months ended March 31, 2019, the Company granted certain performance-based RSUs issued under the 2016 Omnibus Incentive Plan. The RSUs adjusted operating income margin performance target approximates the adjusted operating income margin targets previously disclosed by the Company as part of its effort to support revenue growth and margin expansion. The performance target needs to be achieved for five consecutive quarters before vesting. The performance period begins January 1, 2019 and concludes on December 31, 2022.

**NOTE 3 – COMPREHENSIVE INCOME (LOSS)**

The following summarizes the components of Other comprehensive (loss) income, net of tax, for the three months ended March 31, 2019 and 2018:

(in millions)	Three Months Ended	
	2019	2018
Foreign currency translation (losses) gains	\$ (71.9)	\$ 84.0
Foreign currency translation gain (loss) on hedges of net investments	10.6	(18.9)

These amounts are recorded in Accumulated other comprehensive loss ("AOCI"), net of any related tax adjustments. At March 31, 2019 and December 31, 2018, the cumulative tax adjustments were \$146.6 million and \$157.4 million, respectively, primarily related to foreign currency translation gains and losses.

The cumulative foreign currency translation adjustments included translation losses of \$244.9 million and \$172.9 million at March 31, 2019 and December 31, 2018, respectively, and cumulative losses on loans designated as hedges of net investments of \$101.1 million and \$111.8 million, respectively. These foreign currency translation losses were partially offset by movements on derivative financial instruments.

Changes in AOCI, net of tax, by component for the three months ended March 31, 2019 and 2018 were as follows:

(in millions)	Foreign Currency Translation (Loss)	Gain (Loss) on Cash Flow Hedges	(Loss) Gain on Net Investment Hedges	Pension Liability (Loss) Gain	Total
Balance, net of tax, at December 31, 2018	\$ (284.7)	\$ 0.6	\$ (111.4)	\$ (83.2)	\$ (478.7)
Other comprehensive (loss) income before reclassifications and tax impact	(59.9)	(7.7)	18.6	—	(49.0)
Tax (expense) benefit	(1.4)	2.4	(11.8)	—	(10.8)
Other comprehensive (loss) income,	(61.3)	(5.3)	6.8	—	(59.8)

net of tax, before reclassifications										
Amounts reclassified from accumulated other comprehensive income, net of tax	—	0.2	—	0.9	1.1					
Net (decrease) increase in other comprehensive loss	(61.3)	(5.1)	6.8	0.9	(58.7)					
Balance, net of tax, at March 31, 2019	\$	(346.0)	\$	(4.5)	\$	(104.6)	\$	(82.3)	\$	(537.4)

Edgar Filing: DENTSPLY SIRONA Inc. - Form 10-Q

(in millions)	Foreign Currency Translation (Loss) Gain	(Loss) Gain on Cash Flow Hedges	(Loss) Gain on Net Investment Hedges	Net Unrealized Holding Gain on Available-for-sale Securities	Pension Liability (Loss) Gain	Total
Balance, net of tax, at December 31, 2017	\$ (104.5)	\$ (12.6)	\$ (127.6)	\$ 44.3	\$ (90.6)	\$ (291.0)
Other comprehensive income (loss) before reclassifications and tax impact	84.3	(7.0)	(17.9)	—	—	59.4
Tax (expense) benefit	(19.2)	1.3	9.3	—	—	(8.6)
Other comprehensive income (loss), net of tax, before reclassifications	65.1	(5.7)	(8.6)	—	—	50.8
Amounts reclassified from accumulated other comprehensive income (loss), net of tax	—	2.3	—	(44.3)	1.2	(40.8)
Net increase (decrease) in other comprehensive loss	65.1	(3.4)	(8.6)	(44.3)	1.2	10.0
Balance, net of tax, at March 31, 2018	\$ (39.4)	\$ (16.0)	\$ (136.2)	\$ —	\$ (89.4)	\$ (281.0)

Reclassifications out of AOCI to the Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018 were as follows:

Amounts Reclassified from AOCI (in millions)	Three Months Ended		Affected Line Item in the Consolidated Statements of Operations
	2019	2018	
<b>Loss on derivative financial instruments:</b>			
Interest rate swaps	\$ (0.6)	\$ (0.6)	Interest expense
Foreign exchange forward contracts	0.4	(1.8)	Cost of products sold
Net loss before tax	(0.2)	(2.4)	
Tax impact	—	0.1	Provision for income taxes
Net loss after tax	\$ (0.2)	\$ (2.3)	

**Amortization of defined benefit pension and other postemployment benefit items:**

Amortization of prior service benefits	\$ 0.1	\$ —	(a)
Amortization of net actuarial losses	(1.4)	(1.7)	(a)
Net loss before tax	(1.3)	(1.7)	
Tax	0.4	0.5	Provision



**NOTE 4 – EARNINGS PER COMMON SHARE**

<b>Basic Earnings Per Common Share Computation</b> (in millions, except per share amounts)	Three Months Ended	
	2019	2018
Net income attributable to Dentsply Sirona	\$ 39.2	\$ 81.2
Weighted average common shares outstanding	223.3	227.2
Earnings per common share - basic	\$ 0.18	\$ 0.36
<b>Diluted Earnings Per Common Share Computation</b> (in millions, except per share amounts)	Three Months Ended	
	2019	2018
Net income attributable to Dentsply Sirona	\$ 39.2	\$ 81.2
Weighted average common shares outstanding	223.3	227.2
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	1.7	2.7
Total weighted average diluted	225.0	229.9

shares  
outstanding

Earnings per common share - diluted	\$	0.17	\$	0.35
---	----	------	----	------

The calculation of weighted average diluted common shares outstanding excludes stock options and RSUs of 4.5 million equivalent shares of common stock that were outstanding during the three months ended March 31, 2019 because their effect would be antidilutive. There were 1.6 million antidilutive equivalent shares of common stock outstanding during the three months ended March 31, 2018, respectively.

**NOTE 5 – BUSINESS COMBINATIONS**

On May 1, 2018, the Company acquired all of the outstanding shares of privately held OraMetrix, Inc. for \$120.0 million, with an additional payment totaling \$30.0 million, subject to meeting certain earn-out provisions. During the quarter ended March, 31, 2019, the Company paid the earn-out provision. OraMetrix specializes in orthodontic treatment planning software, wire bending, and clear aligner manufacturing and is headquartered in Richardson, Texas.

14

---

## **NOTE 6 – SEGMENT INFORMATION**

The Company has numerous operating businesses covering a wide range of dental consumable products, dental technology and dental equipment products primarily serving the professional dental market, and certain healthcare products. Professional dental products represented approximately 92% of net sales for all periods presented.

The operating businesses are combined into two operating groups, which generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight. These operating groups are considered the Company's reportable segments as the Company's chief operating decision-maker regularly reviews financial results at the operating group level and uses this information to manage the Company's operations. The accounting policies of the segments are consistent with those described in the Company's most recently filed Form 10-K, in the summary of significant accounting policies.

The Company evaluates performance of the segments based on the groups' net third party sales, excluding precious metal content, and segment adjusted operating income. Net third party sales excluding precious metal content is considered a measure not calculated in accordance with US GAAP, and is therefore considered a non-US GAAP measure. Management believes that the presentation of net sales, excluding precious metal content, provides useful information to investors because a portion of Dentsply Sirona's net sales is comprised of sales of precious metals generated through sales of the Company's precious metal dental alloy products, which are used by third parties to construct crown and bridge materials. Due to the fluctuations of precious metal prices and because the cost of the precious metal content of the Company's sales is largely passed through to customers and has minimal effect on earnings, Dentsply Sirona reports net sales both with and without precious metal content to show the Company's performance independent of precious metal price volatility and to enhance comparability of performance between periods. The Company uses its cost of precious metal purchased as a proxy for the precious metal content of sales, as the precious metal content of sales is not separately tracked and invoiced to customers. The Company believes that it is reasonable to use the cost of precious metal content purchased in this manner since precious metal dental alloy sale prices are typically adjusted when the prices of underlying precious metals change. The Company's exclusion of precious metal content in the measurement of net third party sales enhances comparability of performance between periods as it excludes the fluctuating market prices of the precious metal content. The Company also evaluates segment performance based on each segment's adjusted operating income before provision for income taxes and interest. Segment adjusted operating income is defined as operating income before income taxes and before certain corporate headquarter unallocated costs, restructuring and other costs, interest expense, interest income, other expense (income), net, amortization of intangible assets and depreciation resulting from the fair value step-up of property, plant and equipment from acquisitions. The Company's segment adjusted operating income is considered a non-US GAAP measure. A description of the products and services provided within each of the Company's two operating segments is provided below.

During the three months ended March 31, 2019, certain reclassifications have been made to prior year's data in order to conform to current year presentation. Specifically, during the three months ended March 31, 2019, the Company's laboratory dental business moved into the Consumables segment as the products sold from this business are typically made on a recurring basis and have similar sales and operating characteristics as the other businesses in this segment. The Company moved the orthodontics business into the Technologies & Equipment segment to take advantage of the synergies related to digital planning and treatment within this segment. The Company also moved the instruments business into the Technologies & Equipment segment in order to take advantage of the synergies that stem from pairing equipment with instruments, which are often sold in conjunction with each other. The segment information reflects the revised structure for all periods shown.

### **Technologies & Equipment**

This segment is responsible for the worldwide design, manufacture, sales and distribution of the Company's Dental Technology and Equipment Products and Healthcare Consumable Products. These products include dental implants, CAD/CAM systems, orthodontic dental products, imaging systems, treatment centers, instruments as well as consumable medical device products.

**Consumables**

This segment is responsible for the worldwide design, manufacture, sales and distribution of the Company's Dental Consumable Products which include preventive, restorative, endodontic and laboratory dental products.

The following set forth information about the Company's segments for the three months ended March 31, 2019 and 2018:

Third Party Net Sales

(in millions)	Three Months Ended	
	2019	2018
Technologies & Equipment	\$ 520.8	\$ 510.1
Consumables	425.4	446.0
Total net sales	\$ 946.2	\$ 956.1

Third Party Net Sales, Excluding Precious Metal Content

(in millions)	Three Months Ended	
	2019	2018
Technologies & Equipment	\$ 520.8	\$ 510.1
Consumables	414.2	435.7
Total net sales, excluding precious metal content	935.0	945.8
Precious metal content of sales	11.2	10.3
Total net sales, including precious metal content	\$ 946.2	\$ 956.1

Segment Adjusted Operating Income

(in millions)	Three Months Ended	
	2019	2018
Technologies & Equipment	\$ 71.8	\$ 68.5
Consumables	105.7	114.7
Segment adjusted operating income before income taxes	177.5	183.2

and interest

**Reconciling  
items expense  
(income):**

All Other (a)	59.7	52.6
Restructuring and other costs	20.5	10.2
Interest expense	8.4	8.6
Interest income	(1.1)	(0.6)
Other expense (income), net	(13.8)	(34.1)
Amortization of intangible assets	48.2	49.9
Depreciation resulting from the fair value step-up of property, plant and equipment from business combinations	1.8	1.8
Income before income taxes	\$ 53.8	\$ 94.8

(a) Includes the results of unassigned Corporate headquarter costs and inter-segment eliminations.

**NOTE 7 – INVENTORIES**

Inventories are stated at the lower of cost and net realizable value. The cost of inventories determined by the last-in, first-out (“LIFO”) method at March 31, 2019 and December 31, 2018 was \$9.6 million and \$9.0 million, respectively. The cost of remaining inventories was determined by the first-in, first-out (“FIFO”) or average cost methods. If the FIFO method had been used to determine the cost of LIFO inventories, the amounts at which net inventories are stated would be higher than reported at March 31, 2019 and December 31, 2018 by \$11.2 million and \$10.2 million, respectively.

Inventories, net of inventory valuation reserves, consist of the following:

(in millions)	March 31, 2019	December 31, 2018
Finished goods	\$ 392.5	\$ 380.0
Work-in-process	88.5	89.2
Raw materials and supplies	137.2	129.7
Inventories, net	\$ 618.2	\$ 598.9

The inventory valuation allowance was \$105.6 million and \$92.5 million at March 31, 2019 and December 31, 2018, respectively.

17

---

**NOTE 8 – LEASES**

The Company leases real estate, automobiles and equipment under various operating and finance leases. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the implicit rate is not readily determinable in most of the Company's lease agreements, the Company uses its estimated secured incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. Beginning January 1, 2019, any new real estate and equipment operating lease agreements with lease and nonlease components, will be accounted for as a single lease component.

The Company determines if an arrangement is a lease or contains a lease at inception. The Company's leases have remaining lease terms of approximately 1 year to 11 years. Many of the Company's real estate and equipment leases have one or more options to renew, with terms that can extend from 1 to 3 years or more, which are not included in the initial lease term. The Company does not have lease agreements with residual value guarantees, sale-and-leaseback terms or material restrictive covenants. The Company does not have any sublease arrangements.

The net present value of finance and operating lease assets and liabilities were as follows:

(in millions, except percentages)	Location in the Consolidated Balance Sheets	March 31, 2019
Assets		
Current assets		
Finance leases	Property, plant and equipment, net	\$ 1.7
Operating leases	Operating lease right-of-use assets, net	163.9
Total right-of-use assets		\$ 165.6
Liabilities		
Current liabilities		
Finance leases	Notes payable and current portion of long-term debt	\$ 0.3
Operating leases	Accrued liabilities	41.9

Noncurrent liabilities

Finance leases	Long-term debt	1.5
Operating leases	Operating lease liability	125.5
Total lease liabilities		\$ 169.2

**Supplemental information:**

Weighted-average discount rate

Finance leases	3.3 %
Operating leases	3.1 %

Weighted-average remaining lease term in years

Finance leases	7.3
Operating leases	5.8

The lease cost recognized in the Consolidated Statements of Operations for the three months ended were as follows:

(in millions)	March 31, 2019
Finance lease cost	
Amortization of right-of-use assets	\$ 0.1
Operating lease cost	13.2
Short-term lease cost	0.1
Variable lease cost	1.9
Total lease cost	\$ 15.3

The contractual maturity dates of the remaining lease liabilities at March 31, 2019 were as follows:

(in millions)	Finance Leases	Operating Leases	Total
2019, excluding the three months ended March 31, 2019	\$ 0.2	\$ 34.9	\$ 35.1
2020	0.3	38.7	39.0
2021	0.3	29.2	29.5
2022	0.3	20.7	21.0
2023	0.2	15.3	15.5
2024 and beyond	0.8	45.4	46.2
Total lease payments	\$ 2.1	\$ 184.2	\$ 186.3
Less imputed interest	0.3	16.8	17.1
Present value of lease liabilities	\$ 1.8	\$ 167.4	\$ 169.2

The contractual maturity dates presented under prior lease accounting guidance of the remaining rental commitments at December 31, 2018 were as follows:

(in millions)	Finance Leases	Operating Leases	Total
2019	\$ 4.2	\$ 36.6	\$ 40.8
2020	4.2	28.5	32.7
2021	2.5	22.1	24.6
2022	1.8	16.4	18.2
2023	1.3	12.7	14.0
2024 and beyond	1.1	16.9	18.0
Total lease payments	\$ 15.1	\$ 133.2	\$ 148.3

The supplemental cash flow information for the three months ended were as follows:

(in millions)      March 31,  
2019

**Cash paid for  
amounts  
included in the  
measurement  
of lease  
liabilities:**

Operating cash  
flows from      \$      12.6  
operating leases

Financing cash  
flows from      0.1  
finance leases

**Right-of-use  
assets obtained  
in exchange for  
new lease  
liabilities:**

Operating leases      \$      4.3

**NOTE 9 – RESTRUCTURING AND OTHER COSTS****Restructuring Costs**

During the three months ended March 31, 2019, the Company recorded net restructuring costs and other costs of \$20.5 million, which includes net restructuring costs of \$14.2 million. During the three months ended March 31, 2018, the Company recorded net restructuring costs and other cost of \$10.2 million, which includes net restructuring costs of \$7.4 million. These costs are recorded in Restructuring and other costs in the Consolidated Statements of Operations and the associated liabilities are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets.

At March 31, 2019, the Company's restructuring accruals were as follows:

(in millions)	Severance			
	2017 and Prior Plans	2018 Plans	2019 Plans	Total
Balance at December 31, 2018	\$ 26.8	\$ 16.4	\$ —	\$ 43.2
Provisions	1.0	2.0	10.2	13.2
Amounts applied	(9.2)	(4.4)	(0.8)	(14.4)
Change in estimates	(0.1)	(0.1)	—	(0.2)
Balance at March 31, 2019	\$ 18.5	\$ 13.9	\$ 9.4	\$ 41.8

(in millions)	Lease/Contract Terminations			Total
	2017 and Prior Plans	2018 Plans	2019 Plans	
Balance at December 31, 2018	\$ 0.5	\$ 0.1	\$ —	\$ 0.6
Provisions	0.2	—	—	0.2
Amounts applied	(0.1)	(0.1)	—	(0.2)
Balance at March 31, 2019	\$ 0.6	\$ —	\$ —	\$ 0.6

(in millions)	Other Restructuring Costs			
	2017 and Prior Plans	2018 Plans	2019 Plans	Total
Balance at	\$ 2.0	\$ 0.4	\$ —	\$ 2.4

December 31,  
2018

Provisions	0.2	0.5	0.4	1.1
Amounts applied	(0.3)	(0.2)	—	(0.5)
Change in estimate	0.2	(0.3)	—	(0.1)
Balance at March 31, 2019	\$ 2.1	\$ 0.4	\$ 0.4	\$ 2.9

The following provides the year-to-date changes in the restructuring accruals by segment:

(in millions)	December 31, 2018	Provisions	Amounts Applied	Change in Estimates	March 31, 2019
Technologies & Equipment	\$ 41.4	\$ 6.0	\$ (13.1)	\$ —	\$ 34.3
Consumables	5.1	7.6	(1.5)	(0.1)	11.1
All Other	(0.3)	0.9	(0.5)	(0.2)	(0.1)
Total	\$ 46.2	\$ 14.5	\$ (15.1)	\$ (0.3)	\$ 45.3

**Other Costs**

Other costs for the three months ended March 31, 2019 were \$6.3 million, including an impairment charge of \$5.3 million. The impaired indefinite-lived intangible assets were tradenames and trademarks within the Technologies & Equipment segment. Other costs for the three months ended March 31, 2018 were \$2.8 million mostly related to legal settlements.

22

---

**NOTE 10 – FINANCIAL INSTRUMENTS AND DERIVATIVES****Derivative Instruments and Hedging Activities**

The Company's activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates and interest rates. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company's operating results and equity. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert variable rate debt to fixed rate debt.

**Derivative Instruments Designated as Hedging****Cash Flow Hedges**

The following summarizes the notional amounts of cash flow hedges by derivative instrument type at March 31, 2019 and the notional amounts expected to mature during the next 12 months, with a discussion of the various cash flow hedges by derivative instrument type following the table:

(in millions)	Aggregate Notional Amount	Aggregate Notional Amount Maturing within 12 Months
Foreign exchange forward contracts	\$ 369.4	\$ 279.1
Interest rate swaps	263.3	113.3
Total derivative instruments designated as cash flow hedges	\$ 632.7	\$ 392.4

**Foreign Exchange Risk Management**

The Company uses a layered hedging program to hedge select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings of the consolidated Company. The Company accounts for the designated foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the assessed effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time value component of the fair value of the derivative is reported on a straight line basis in Cost of products sold in the Consolidated Statements of Operations in the period which it is applicable. Any cash

flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. The Company hedges various currencies, with the most significant activity occurring in euros, Swedish kronor, Canadian dollars, British pounds, Swiss francs and Australian dollars.

### Interest Rate Risk Management

The Company uses interest rate swaps to convert a portion of its variable interest rate debt to fixed interest rate debt. At March 31, 2019, the Company has one significant exposure hedged with interest rate contracts. The exposure is hedged with derivative contracts having notional amounts totaling 12.6 billion Japanese yen, which effectively converts the underlying variable interest rate debt facility to a fixed interest rate of 0.9% for an initial term of five years ending September 2019. On March 11, 2019, the Company entered into a Treasury Rate Lock ("T-Lock") transaction to hedge the base interest rate variability exposure on a planned \$150 million ten year debt issuance in 2021. The T-Lock is designated as a cash flow hedge of interest rate risk. The T-Lock will be cash settled when the debt is issued, with the fair value of the T-Lock recognized as an asset or liability with an offsetting position in AOCI. As interest is accrued on this debt in the future, a pro-rata amount from AOCI will be released and recorded in Other expense (income) in the Consolidated Statements of Operations.

The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

Cash Flow Hedge Activity

Gains (losses) recorded in AOCI in the Consolidated Balance Sheets and Cost of products sold in the Company's Consolidated Statements of Operations related to all cash flow hedges for the three months ended March 31, 2019 and 2018 were insignificant.

For the rollforward of derivative instruments designated as cash flow hedges in AOCI see Note 3, Comprehensive Income.

**Hedges of Net Investments in Foreign Operations**

The Company has significant investments in foreign subsidiaries the most significant of which are denominated in euros, Swiss francs, Japanese yen and Swedish kronor. The net assets of these subsidiaries are exposed to volatility in currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of this exposure. The derivative instruments consist of foreign exchange forward contracts and cross currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in derivative and non-derivative financial instruments designated as hedges of net investments, which are included in AOCI. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows.

During the three months ended March 31, 2019, the Company early terminated its existing 245.6 million euro cross currency basis swap and entered into a new 263.4 million euro cross currency basis swap maturing in August 2021. The cross currency basis swap is designated as a hedge of net investments. This contract effectively converts the \$295.7 million bond coupon from 4.1% to 1.2%, which will result in a net reduction of interest expense through maturity in 2021. The early termination resulted in a cash receipt of \$17.4 million.

The following summarizes the notional amount of hedges of net investments by derivative instrument at March 31, 2019 and the notional amounts expected to mature during the next 12 months:

(in millions)	Aggregate Notional Amount	Aggregate Notional Amount Maturing within 12 Months
Foreign exchange forward contracts	\$ 765.5	\$ 255.2
Cross currency basis swaps	295.5	—
Total for instruments not designated as hedges	\$ 1,061.0	\$ 255.2

The following summarizes the amount of gains (losses) recorded in AOCI in the Consolidated Balance Sheets and Other expense (income), net in the Company's Consolidated Statements of Operations related to the hedges of net investments for the three months ended March 31, 2019 and 2018:

March 31, 2019			
(in millions)	Gain in AOCI	Consolidated Statements of Operations Location	Recognized in Income (Expense)
<b>Effective Portion:</b>			
Cross currency basis swaps	\$ 3.1	Interest expense	\$ 2.0
Foreign exchange forward contracts	15.5	Other expense (income), net	3.5
Total for net investment hedging	\$ 18.6		\$ 5.5

	March 31, 2018		
(in millions)	Loss in AOCI	Consolidated Statements of Operations Location	Recognized in Income (Expense)
<b>Effective Portion:</b>			
Cross currency basis swaps	\$ (6.4)	Interest expense	\$ 1.7
		Other expense (income), net	(6.6)
Foreign exchange forward contracts	(11.5)	Other expense (income), net	1.5
Total for net investment hedging	\$ (17.9)		\$ (3.4)

#### Derivative Instruments Not Designated as Hedges

The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other expense (income), net in the Consolidated Statements of Operations. The Company primarily uses foreign exchange forward contracts to hedge these risks. Any cash flows associated with the foreign exchange forward contracts and interest rate swaps not designated as hedges are included in cash from operating activities in the Consolidated Statements of Cash Flows.

The following summarizes the aggregate notional amounts of the Company's economic hedges not designated as hedges by derivative instrument types at March 31, 2019 and the notional amounts expected to mature during the next 12 months:

(in millions)	Aggregate Notional Amount	Aggregate Notional Amount Maturing within 12 Months
Foreign exchange forward contracts	\$ 410.9	\$ 270.4
Total for instruments not designated as hedges	\$ 410.9	\$ 270.4

Gains (losses) recorded in the Company's Consolidated Statements of Operations related to the economic hedges not designated as hedging for the three months ended March 31, 2019 and 2018 were insignificant.

**Balance Sheet Offsetting**

Substantially all of the Company's derivative contracts are subject to netting arrangements, whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets.

25

---

Offsetting of financial liabilities under netting arrangements at March 31, 2019 were insignificant. Offsetting of financial assets under netting arrangements at March 31, 2019 were as follows:

(in millions)	Gross Amounts Recognized	Gross Amount Offset in the Consolidated Balance Sheets	Net Amounts Presented in the Consolidated Balance Sheets	Gross Amounts Not Offset in the Consolidated Balance Sheets		Net Amount
				Financial Instruments	Cash Collateral Received/Pledged	
<b>Assets</b>						
Foreign exchange forward contracts	\$ 45.2	\$ —	\$ 45.2	\$ (8.1)	\$ —	\$ 37.1
Cross currency basis swaps	1.0	—	1.0	(0.4)	—	0.6
Total Assets	\$ 46.2	\$ —	\$ 46.2	\$ (8.5)	\$ —	\$ 37.7

Offsetting of financial liabilities under netting arrangements at December 31, 2018 were insignificant. Offsetting of financial assets under netting arrangements at December 31, 2018 were as follows:

(in millions)	Gross Amounts Recognized	Gross Amount Offset in the Consolidated Balance Sheets	Net Amounts Presented in the Consolidated Balance Sheets	Gross Amounts Not Offset in the Consolidated Balance Sheets		Net Amount
				Financial Instruments	Cash Collateral Received/Pledged	
<b>Assets</b>						
Foreign exchange forward contracts	\$ 33.7	\$ —	\$ 33.7	\$ (1.8)	\$ —	\$ 31.9
Cross currency basis	11.6	—	11.6	(1.6)	—	10.0

swaps

Total Assets	\$	45.3	\$	—	\$	45.3	\$	(3.4)	\$	—	\$	41.9
--------------	----	------	----	---	----	------	----	-------	----	---	----	------

**NOTE 11 – FAIR VALUE MEASUREMENT**

The Company records financial instruments at fair value with unrealized gains and losses related to certain financial instruments reflected in AOCI in the Consolidated Balance Sheets. In addition, the Company recognizes certain liabilities at fair value. The Company applies the market approach for recurring fair value measurements. Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities that are recorded at fair value as of the balance sheet date are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The fair value of financial instruments is determined by reference to various market data and other valuation techniques as appropriate. The Company believes the carrying amounts of cash and cash equivalents, accounts receivable (net of allowance for doubtful accounts), prepaid expenses and other current assets, accounts payable, accrued liabilities, income taxes payable and notes payable approximate fair value due to the short-term nature of these instruments. The Company estimated the fair value using Level 1 inputs and carrying value of total long-term debt, including the current portion, was \$1,569.7 million and \$1,565.8 million, respectively at March 31, 2019. At December 31, 2018, the Company estimated the fair value and carrying value of total long-term debt, including the current portion, was \$1,577.1 million and \$1,575.5 million, respectively. The variable interest rate on the Japanese yen term loan is consistent with current market conditions, therefore the fair value approximates the loan's carrying value.

The following set forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis at March 31, 2019 and both assets and liabilities at December 31, 2018:

(in millions)	March 31, 2019			
	Total	Level 1	Level 2	Level 3
<b>Assets</b>				
Cross currency basis swaps	\$ 1.0	\$ —	\$ 1.0	\$ —
Foreign exchange forward contracts	46.0	—	46.0	—
Total assets	\$ 47.0	\$ —	\$ 47.0	\$ —
<b>Liabilities</b>				
Interest rate swaps	\$ 3.5	\$ —	\$ 3.5	\$ —
Foreign exchange forward contracts	5.8	—	5.8	—
Contingent considerations on acquisitions	9.1	—	—	9.1
Total liabilities	\$ 18.4	\$ —	\$ 9.3	\$ 9.1

(in millions)	December 31, 2018			
	Total	Level 1	Level 2	Level 3
<b>Assets</b>				
Cross currency basis swaps	\$ 11.6	\$ —	\$ 11.6	\$ —
Foreign exchange forward contracts	33.7	—	33.7	—
Total assets	\$ 45.3	\$ —	\$ 45.3	\$ —
<b>Liabilities</b>				
Interest rate swaps	\$ 0.2	\$ —	\$ 0.2	\$ —
Foreign exchange forward contracts	3.2	—	3.2	—
Contingent considerations on acquisitions	9.1	—	—	9.1
Total liabilities	\$ 12.5	\$ —	\$ 3.4	\$ 9.1

There have been no transfers between levels during the three months ended March 31, 2019.

Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates and credit risks. The Company utilizes interest rate swaps and foreign exchange forward contracts that are considered cash flow hedges. In addition, the Company at times employs forward exchange contracts that are considered hedges of net investment in foreign operations. Designated derivative instruments are further discussed in Note 10, Financial Instruments and Derivatives.

28

---

## **NOTE 12 – INCOME TAXES**

### **Uncertainties in Income Taxes**

The Company recognizes in the interim consolidated financial statements, the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position.

It is reasonably possible that certain amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date of the Company's interim consolidated financial statements. Final settlement and resolution of outstanding tax matters in various jurisdictions during the next twelve months are not expected to be significant.

### **Other Tax Matters**

During the three months ended March 31, 2019, the Company recorded \$2.4 million of tax expense for discrete tax matters. The Company also recorded a \$1.5 million tax benefit related to the indefinite-lived intangible asset impairment charge recorded during the quarter.

During the quarter ended March 31, 2018, the Company recorded the following discrete tax items, \$2.2 million of excess tax benefit related to employee share-based compensation, tax expense of \$1.2 million million related to valuation allowances, \$0.2 million of tax expense related to enacted statutory rate changes, \$7.2 million of tax expense for other discrete tax matters and \$3.4 million million tax benefit related to U.S. tax reform. The Company also recorded \$1.1 million of tax expense as a discrete item related to the gain on sale of marketable securities.

**NOTE 13 – FINANCING ARRANGEMENTS**

At March 31, 2019 and December 31, 2018, there were no outstanding borrowings under the current \$700.0 million multi currency revolving credit facility. The Company had no outstanding borrowings under the commercial paper facility at March 31, 2019 and \$67.8 million outstanding under the commercial paper facility at December 31, 2018. The multi-currency revolving credit facility serves as a back-stop facility for the Company's \$500.0 million commercial paper program.

At March 31, 2019, the Company had \$719.9 million of borrowing available under lines of credit, including lines available under its short-term arrangements and revolving credit agreement.

The Company's revolving credit facility, term loans and Senior Notes contain certain affirmative and negative covenants relating to the Company's operations and financial condition. At March 31, 2019, the Company was in compliance with all debt covenants.

On March 11, 2019, the Company entered into a T-Lock which expires on September 30, 2021, to hedge the base interest rate variability exposure on a planned ten-year debt issuance in 2021. The T-Lock is designated as a cash flow hedge of interest rate risk fixing the base rate at 2.84% on a notional amount of \$150 million. The T-Lock will be cash settled when the debt is issued, with the fair value of the T-Lock recognized as an asset or liability with an offsetting position in AOCI. As interest is accrued on this debt, a pro-rata amount from AOCI will be released and recorded in Other expense (income), net in the Consolidated Statements of Operation.

30

---

**NOTE 14 – GOODWILL AND INTANGIBLE ASSETS**

A reconciliation of changes in the Company's goodwill by reportable segment is as follows (the segment information below reflects the current structure for all periods shown):

(in millions)	Technologies & Equipment	Consumables	Total
Balance at December 31, 2018	\$ 2,579.8	\$ 851.5	\$ 3,431.3
Business unit transfers	(37.1)	37.1	—
Effects of exchange rate changes	13.3	(45.4)	(32.1)
Balance at March 31, 2019	\$ 2,556.0	\$ 843.2	\$ 3,399.2

During the three months ended March 31, 2019, the Company transferred goodwill between segments due to changes in the reporting units as a result of the realignment of certain businesses between segments. Affected reporting units were tested for potential impairment of goodwill before the transfers. No goodwill impairment was identified.

The following provides the gross carrying amount of goodwill and the cumulative goodwill impairment:

(in millions)	March 31, 2019			December 31, 2018		
	Gross Carrying Amount	Cumulative Impairment	Net Carrying Amount	Gross Carrying Amount	Cumulative Impairment	Net Carrying Amount
Technologies & Equipment	\$ 5,292.6	\$ (2,736.6)	\$ 2,556.0	\$ 5,247.9	\$ (2,668.1)	\$ 2,579.8
Consumables	\$ 843.2	—	\$ 843.2	\$ 920.0	\$ (68.5)	\$ 851.5
Total effect of cumulative impairment	\$ 6,135.8	\$ (2,736.6)	\$ 3,399.2	\$ 6,167.9	\$ (2,736.6)	\$ 3,431.3

Identifiable definite-lived and indefinite-lived intangible assets consist of the following:

(in millions)	March 31, 2019			December 31, 2018		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount

Edgar Filing: DENTSPLY SIRONA Inc. - Form 10-Q

Patents	\$ 1,351.9	\$ (428.0)	\$ 923.9	\$ 1,376.4	\$ (407.1)	\$ 969.3
Tradenames and trademarks	79.1	(61.9)	17.2	81.1	(62.5)	18.6
Licensing agreements	35.9	(26.6)	9.3	36.1	(26.3)	9.8
Customer relationships	1,072.2	(348.0)	724.2	1,085.3	(334.4)	750.9
Total definite-lived	\$ 2,539.1	\$ (864.5)	\$ 1,674.6	\$ 2,578.9	\$ (830.3)	\$ 1,748.6
Indefinite-lived tradenames and trademarks	\$ 650.1	\$ —	\$ 650.1	\$ 671.7	\$ —	\$ 671.7
Total identifiable intangible assets	\$ 3,189.2	\$ (864.5)	\$ 2,324.7	\$ 3,250.6	\$ (830.3)	\$ 2,420.3

During the three months ended March 31, 2019, the Company impaired \$5.3 million of product tradenames and trademarks within the Technologies & Equipment segment. The impairment was the result of a change in forecasted sales related to divestitures of non-strategic product lines.

31

---

## NOTE 15 – COMMITMENTS AND CONTINGENCIES

### Litigation

The SEC's Division of Enforcement has asked the Company to provide documents and information concerning the Company's accounting and disclosures. The Company is cooperating with the SEC's investigation. The Company is unable to predict the ultimate outcome of this matter, or whether it will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.

On January 11, 2018, Tom Redlich, a former employee, filed a lawsuit against the Company, demanding supplemental compensation pursuant to an agreement allegedly entered into with Sirona Dental GmbH which was intended to entice Mr. Redlich to continue to work for the company for no less than eight years following the date of this agreement. The Company filed its response on April 4, 2018, denying the authenticity and enforceability of, and all liability under, the alleged agreement. The court held an initial hearing on the matter on April 11, 2018. Mr. Redlich filed his reply on July 9, 2018. The Company filed its response to that reply on August 23, 2018, refuting the allegations in Mr. Redlich's reply and continuing to deny liability under the alleged agreement. Following that, Mr. Jost Fischer, upon invitation of the Company, joined the litigation against Mr. Redlich as a third party. The court held a hearing on August 30, 2018 where the parties outlined their respective legal positions. In late November 2018, Mr. Fischer filed a statement to the court in which he disputed the central allegations raised by Mr. Redlich in his lawsuit and his supplemental submissions to the court. Based on Mr. Fischer's statement, the Company filed a further written statement to the court, therein insisting on its previous legal position and presenting new factual submissions and evidence. In response, Mr. Redlich filed a written statement rejecting the positions of Mr. Fischer and the Company. In late January 2019 the court held hearings in which Mr. Redlich and a number of witnesses provided oral testimony to the court. In early April 2019, the court held a hearing, receiving additional testimony and the court plans to conduct a further hearing in the matter on May 29, 2019. The Company continues to defend against this claim vigorously.

On January 25, 2018, Futuredontics, Inc. received service of a purported class action lawsuit brought by Henry Olivares and other similarly situated individuals in the Superior Court of the State of California for the County of Los Angeles. In January 2019, an amended complaint was filed adding another named plaintiff, Rachael Clarke, and various claims. The plaintiff class alleges several violations of the California wage and hours laws, including, but not limited to, failure to provide rest and meal breaks and the failure to pay overtime. The parties have engaged in written and other discovery. On February 5, 2019, Plaintiff Caethia Holt (represented by the same counsel as Mr. Olivares and Ms. Clarke) filed a separate representative action in Los Angeles Superior Court alleging a single violation of the Private Attorneys' General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. The Company has not yet been served in connection with this action. On April 5, 2019, Plaintiff Kendra Cato filed a similar action in Los Angeles Superior Court alleging a single violation of the Private Attorneys' General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. The Company has been served with the Cato complaint. The Company continues to vigorously defend against these matters.

On June 7, 2018, and August 9, 2018, John Castronovo and Irving Golombeck, respectively, filed substantially identical putative class action suits in the Supreme Court of the State of New York, County of New York claiming that the Company, certain of its present and former officers and directors, and former officers and directors of Sirona violated U.S. securities laws (together, the "State Court Class Action"). The plaintiffs allege that the registration statement/joint proxy statement filed with the SEC on December 4, 2015 (the "Registration Statement") in connection with the Merger contained material misrepresentations and omitted required information by failing to disclose, among other things, that a distributor had allegedly purchased excessive inventory of legacy Sirona products and that three distributors of the Company's and Sirona's products and equipment had allegedly been engaging in anticompetitive conduct. The plaintiffs assert these claims on behalf of a putative class of former shareholders of Sirona who exchanged their shares of Sirona stock for shares of the Company's stock in the Merger. On September 19, 2018, the

Court consolidated the two actions.

On October 9, 2018, defendants filed a motion to stay discovery pending determination of their motion to dismiss. Plaintiffs filed an amended complaint on November 2, 2018 and defendants moved to dismiss the amended complaint on December 17, 2018. Oral argument on the motion to stay discovery took place on January 2, 2019. Plaintiffs filed their opposition to the motion to dismiss on January 31, 2019, and defendants' reply in further support was filed on March 1, 2019.

On December 19, 2018, Boynton Beach Employees' Pension Plan filed a putative class action in the U.S. District Court for the Eastern District of New York, alleging that the Company, certain of its present and former officers and directors, and former officers and directors of Sirona violated U.S. securities laws (the "Federal Class Action"). The plaintiff alleges the same claims as those asserted in the State Court Class Action, relating to the alleged material misrepresentations and omissions of required information in the Registration Statement. In addition, the plaintiff alleges that the defendants made false and misleading

32

---

statements in quarterly and annual reports and other public statements between February 20, 2014, and August 7, 2018. The plaintiff asserts claims on behalf of a putative class consisting of (a) all purchasers of the Company's stock during the period February 20, 2014 through August 7, 2018, (b) former shareholders of Sirona who exchanged their shares of Sirona stock for shares of the Company's stock in the Merger, and (c) holders of the Company's shares who held shares as of the record date of December 2, 2015 and were entitled to vote with respect to the Merger. Motions for appointment of lead plaintiff and lead counsel were filed on February 19, 2019.

On April 29, 2019, John Behrmann and Nancy Behrmann, purported stockholders of the Company, filed a derivative action on behalf of the Company in the District of Delaware against the Company's Directors. Specifically, Plaintiffs allege that the Directors breached their fiduciary duties by causing the Company to improperly misrepresent the business prospects of the Company, including regarding the existence of an alleged antitrust scheme between the Company and three of its distributors. Plaintiffs also claim that the Directors' misconduct has subjected the Company to multiple securities class actions and other litigation. Based on the same set of factual allegations, Plaintiffs assert additional claims against the directors for unjust enrichment, gross mismanagement, waste of corporate assets, and violations of sections 10(b) and 14(a) of the Exchange Act and SEC Rules 10b-5 and 14a-9. Plaintiffs are seeking monetary damages and various corporate governance reforms.

On January 25, 2019, defendants moved to stay all proceedings in the State Court Class Action pending final disposition of the Federal Class Action and on March 27, 2019, the court held a hearing on the motion to stay and the motion to dismiss. The Company intends to defend itself vigorously in these actions.

As a result of an audit by the IRS for fiscal years 2012 through 2013, on February 11, 2019, the IRS issued to the Company a "30-day letter" and a Revenue Agent's Report ("RAR"), relating to the Company's worthless stock deduction in 2013 in the amount of \$546.0 million. The RAR disallows the deduction and, after adjusting the Company's net operating loss carryforward, asserts that the Company is entitled to a refund of \$4.7 million for 2012, has no tax liability for 2013, and owes a deficiency of \$17.1 million in tax for 2014, excluding interest. In accordance with ASC 740, the Company recorded the tax benefit associated with the worthless stock deduction in the Company's 2012 financial statements. The Company will submit a formal protest disputing on multiple grounds the proposed taxes.

The Company believes the IRS position is without merit and believes that it is more likely-than-not that the Company's position will be sustained upon further review. The Company has not accrued a liability relating to the proposed tax adjustments. However, the outcome of this dispute involves a number of uncertainties, including those inherent in the valuation of various assets at the time of the worthless stock deduction, and those relating to the application of the Internal Revenue Code and other federal income tax authorities and judicial precedent. Accordingly, there can be no assurance that the dispute with the IRS will be resolved favorably. If determined adversely, the dispute would result in a current period charge to earnings and could have a material adverse effect in the consolidated results of operations, financial position and liquidity of the Company.

The Swedish Tax Agency has disallowed certain of the Company's interest expense deductions for the tax years from 2013 to 2017 and is also expected to do the same for the 2018 tax year. If such interest expense deductions were disallowed, the Company would be subject to an additional \$41.0 million in tax expense. The Company has appealed the disallowance to the Swedish administrative court. With respect to such deductions taken in the tax years from 2013 to 2014, the court ruled against the Company on July 5, 2017. On August 7, 2017, the Company appealed the unfavorable decision of the Swedish administrative court. On November 5, 2018, the Company delivered its final argument to the administrative court of appeal at a hearing. The European Union Commission has taken the view that Sweden's interest deduction limitation rules are incompatible with European Union law and supporting legal opinions, and therefore the Company has not paid the tax or made provision in its financial statements for such potential expense. The Company intends to vigorously defend its position and pursue related appeals.

In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company's products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory damages. Based upon the Company's experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company's business, financial condition, results of operations or liquidity.

While the Company maintains general, product, property, workers' compensation, automobile, cargo, aviation, crime, fiduciary and directors' and officers' liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses.

**Purchase Commitments**

From time to time, the Company enters into long-term inventory purchase commitments with minimum purchase requirements for raw materials and finished goods to ensure the availability of products for production and distribution. These commitments may have a significant impact on levels of inventory maintained by the Company.

## **DENTSPLY SIRONA Inc. and Subsidiaries**

### **Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations**

Information included in or incorporated by reference in this Form 10-Q, and other filings with the U. S. Securities and Exchange Commission (the “SEC”) and the Company’s press releases or other public statements, contains or may contain forward-looking statements. Please refer to a discussion of the Company’s forward-looking statements and associated risks in Part I, “Forward-Looking Statements” and Part I, Item 1. “Business” of the Company's Form 10-K for the year ended December 31, 2018.

#### **OVERVIEW**

##### **Highlights**

- For the three months ended March 31, 2019, net sales decreased 1.0% compared to the three months ended March 31, 2018. On a constant currency basis sales increased 3.6% compared to the three months ended March 31, 2018.
- For the three months ended March 31, 2019, the Company generated earnings per diluted common share of \$0.17 compared to earnings per diluted common share of \$0.35 for the three months ended March 31, 2018. Adjusted earnings per diluted common share (a non-US GAAP measure as reconciled under net income attributable to Dentsply Sirona below) for the three months ended March 31, 2019 was \$0.49 compared to \$0.45 earnings per diluted common share for the three months ended March 31, 2018.
- Cash flow from operations for the first three months of 2019 was \$29.3 million, as compared to \$55.1 million in the first three months of 2018.

##### **Company Profile**

Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. As The Dental Solutions Company, Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry. Dentsply Sirona’s global headquarters is located in York, Pennsylvania. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY.

#### **BUSINESS**

The Company operates in two business segments:

The Technologies & Equipment segment is responsible for the worldwide design, manufacture, sales and distribution of the Company’s Dental Technology and Equipment Products and Healthcare Consumable Products. These products include dental implants, CAD/CAM systems, orthodontic dental products, imaging systems, treatment centers, instruments as well as consumable medical device products.

The Consumables segment is responsible for the worldwide design, manufacture, sales and distribution of the Company’s Dental Consumable Products which include preventive, restorative, endodontic and laboratory dental products.



## Principal Measurements

The principal measurements used by the Company in evaluating its business are: (1) constant currency sales growth by segment and geographic region; (2) internal sales growth by segment and geographic region; and (3) adjusted operating income and margins of each reportable segment, which excludes the impacts of purchase accounting, corporate expenses, and certain other items to enhance the comparability of results period to period. These principal measurements are not calculated in accordance with accounting principles generally accepted in the United States; therefore, these items represent non-US GAAP measures. These non-US GAAP measures may differ from other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

The Company defines “constant currency” sales growth as the increase or decrease in net sales from period to period excluding precious metal content and the impact of changes in foreign currency exchange rates. This impact is calculated by comparing current-period revenues to prior-period revenues, with both periods converted at the U.S. dollar to local currency foreign exchange rate for each month of the prior period, for the currencies in which the Company does business. The Company defines “internal” sales growth as constant currency sales growth excluding the impacts of net acquisitions and divestitures and discontinued products.

## Business Drivers

The primary drivers of internal growth include macroeconomic factors, global dental market growth, innovation and new product launches by the Company, as well as continued investments in sales and marketing resources, including clinical education. Management believes that the Company’s ability to execute its strategies should allow it to grow faster than the underlying dental market over time. On a short-term basis, changes in strategy or distributor inventory levels can impact the Company’s internal growth.

The Company has a focus on maximizing operational efficiencies on a global basis. The Company has expanded the use of technology as well as process improvement initiatives to enhance global efficiency. In addition, management continues to evaluate the consolidation of operations and functions, as part of integration activities, to further reduce costs. While the Company continues implementing integration related activities, which can have an adverse impact on reported results, the Company expects that the continued benefits from these global efficiency and integration initiatives will improve its cost structure.

In connection with these initiatives, the Board of Directors of the Company approved a plan to restructure the Company’s business to support revenue growth and margin expansion and to simplify the organization, with the understanding that such restructuring plan may continue to evolve as the Company progresses through the continued planning and execution of the plan. The plan includes a restructuring of the business through streamlining the organization and consolidating functions. The restructuring plan anticipates a net reduction in the Company’s global workforce of approximately 6% to 8%, and the Company will consult with employee representation in connection with the execution of the restructuring plan where required. The Company's goal is that the restructuring will result in annualized topline growth of 3% to 4%, an adjusted operating income margin of 20% by the end of the year 2020, an adjusted operating income margin of 22% by the year 2022 and \$200 million to \$225 million in net annual cost savings by 2021. The Company expects to incur approximately \$275 million in one-time expenditures and charges. There can be no assurance that the cost reductions and results will be achieved.

As part of this restructuring plan, the Company is creating more meaningful solutions for dentists built around innovative products and differentiated clinical education. In order to achieve this goal, the Company introduced five key operating principles:

•*Approach customers as one:* Put the customer at the center of how Dentsply Sirona is organized. The Company is creating one integrated approach to customer service, direct and indirect selling, and clinical education to strengthen the relationship with the customer and better serve the customers' needs.

•*Assume greater responsibility for Dentsply Sirona's demand creation:* To better support dealer partners and end-user customers, the Company launched a sales force effectiveness program, with a view to improving returns on sales and marketing investments.

•*Ensure that innovation is substantial and supported:* Create a comprehensive R&D program that prioritizes spending across the entire Company portfolio resulting in more impactful innovations each year.

- Lead in clinical education:* Dentsply Sirona is investing to further its leadership position through local training events and enhancing online training presence to strengthen the relationship with the dental professionals.

- Take advantage of scale:* The Company is focused on integrating its dental product portfolios to unlock operational efficiencies, including performance improvements in procurement, logistics, manufacturing, sales force and marketing programs. In addition, Dentsply Sirona is taking significant measures to simplify the business. In combination, these initiatives will improve organizational efficiency and better leverage the Company's selling, general and administrative infrastructure.

Product innovation is a key component of the Company's overall growth strategy. New advances in technology are anticipated to have a significant influence on future products in the dentistry and consumable medical device markets in which the Company operates. As a result, the Company continues to pursue research and development initiatives to support technological development, including collaborations with various research institutions and dental schools. In addition, the Company licenses and purchases technologies developed by third parties. Although the Company believes these activities will lead to new innovative dental, healthcare consumable and dental technology products, they involve new technologies and there can be no assurance that commercialized products will be developed.

The Company will continue to pursue opportunities to expand the Company's product offerings, technologies and sales and service infrastructure through partnerships and acquisitions. Although the professional dental and the consumable medical device markets in which the Company operates have experienced consolidation, they remain fragmented. Management believes that there will continue to be adequate opportunities to participate as a consolidator in the industry for the foreseeable future.

The Company's business is subject to quarterly fluctuations of consolidated net sales and net income. Price increases, promotional activities as well as changes in inventory levels at distributors contribute to this fluctuation. The Company typically implements most of its price increases in October or January of a given year across most of its businesses. Distributor inventory levels tend to increase in the period leading up to a price increase and decline in the period following the implementation of a price increase. Required minimum purchase commitments under agreements with key distributors may increase inventory levels in excess of retail demand. These net inventory changes have impacted the Company's consolidated net sales and net income in the past, and may continue to do so in the future, over a given period or multiple periods. In addition, the Company may from time to time, engage in new distributor relationships that could cause quarterly fluctuations of consolidated net sales and net income. Distributor inventory levels may fluctuate, and may differ from the Company's predictions, resulting in the Company's projections of future results being different than expected. There can be no assurance that the Company's dealers and customers will maintain levels of inventory in accordance with the Company's predictions or past history, or that the timing of customers' inventory build or liquidation will be in accordance with the Company's predictions or past history. Any of these fluctuations could be material to the Company's consolidated financial statements.

### **Impact of Foreign Currencies and Interest Rates**

Due to the Company's significant international presence, movements in foreign exchange and interest rates may impact the Consolidated Statements of Operations. With approximately two-thirds of the Company's net sales located in regions outside the United States, the Company's consolidated net sales are impacted negatively by the strengthening or positively impacted by the weakening of the U.S. dollar. Additionally, movements in certain foreign exchange rates may unfavorably or favorably impact the Company's results of operations, financial condition and liquidity as a number of the Company's manufacturing and distribution operations are located outside of the U.S.

### **Reclassification of Prior Year Amounts**

During the three months ended March 31, 2019, certain reclassifications have been made to prior year's data in order to conform to current year presentation. Specifically, during the three months ended March 31, 2019, the Company's laboratory dental business moved into the Consumables segment as the products sold from this business are typically made on a recurring basis and have similar sales and operating characteristics as the other businesses in this segment. The Company moved the orthodontics business into the Technologies & Equipment segment to take advantage of the synergies related to digital planning and treatment within this segment. The Company also moved the instruments business into the Technologies & Equipment segment in order to take advantage of the synergies that stem from pairing equipment with instruments, which are often sold in conjunction with each other. The segment information reflects the revised structure for all periods shown.

## RESULTS OF OPERATIONS, QUARTER ENDED MARCH 31, 2019 COMPARED TO QUARTER ENDED MARCH 31, 2018

### Net Sales

The discussion below summarizes the Company's sales growth which excludes precious metal content, into the following components: (1) constant currency sales growth, which includes internal sales growth and net acquisition sales growth, and (2) foreign currency impacts. These disclosures of net sales growth provide the reader with sales results on a comparable basis between periods.

Management believes that the presentation of net sales, excluding precious metal content, provides useful information to investors because a portion of Dentsply Sirona's net sales is comprised of sales of precious metals generated through sales of the Company's precious metal dental alloy products, which are used by third parties to construct crown and bridge materials. Due to the fluctuations of precious metal prices and because the cost of the precious metal content of the Company's sales is largely passed through to customers and has minimal effect on earnings, Dentsply Sirona reports net sales both with and without precious metal content to show the Company's performance independent of precious metal price volatility and to enhance comparability of performance between periods. The Company uses its cost of precious metal purchased as a proxy for the precious metal content of sales, as the precious metal content of sales is not separately tracked and invoiced to customers. The Company believes that it is reasonable to use the cost of precious metal content purchased in this manner since precious metal dental alloy sale prices are typically adjusted when the prices of underlying precious metals change.

The presentation of net sales, excluding precious metal content, is considered a measure not calculated in accordance with US GAAP, and is therefore considered a non-US GAAP measure. The Company provides the following reconciliation of net sales to net sales, excluding precious metal content. The Company's definitions and calculations of net sales, excluding precious metal content, and other operating measures derived using net sales, excluding precious metal content, may not necessarily be the same as those used by other companies.

(in millions)	Three Months Ended			
	March 31,		\$ Change	% Change
2019	2018			
Net sales	\$ 946.2	\$ 956.1	\$ (9.9)	(1.0%)
Less: precious metal content of sales	11.2	10.3	0.9	8.7%
Net sales, excluding precious metal content	\$ 935.0	\$ 945.8	\$ (10.8)	(1.1%)

Reported net sales, for the three months ended March 31, 2019 were \$946.2 million, a decrease of \$9.9 million from the three months ended March 31, 2018. Net sales, excluding precious metal content, for the three months ended March 31, 2019 were \$935.0 million, a decrease of \$10.8 million from the three months ended March 31, 2018. Based on the Company's estimate, inventory held by certain distributors decreased by approximately \$8 million during the three months ended March 31, 2018. Net sales, excluding precious metal content, were negatively impacted by

approximately 4.7% due to the strengthening of the U.S. dollar as compared to the prior year period

For the three months ended March 31, 2019, net sales, excluding precious metal content, increased 3.6% on a constant currency basis. This includes a benefit of 60 basis points from acquisitions and an unfavorable impact from discontinued products of 90 basis points, which results in internal sales growth of 3.9%. The internal sales growth was attributable to the Technologies & Equipment segment.

**Sales Growth by Region**

Net sales, excluding precious metal content, by geographic region is as follows:

(in millions)	Three Months Ended March 31,			
	2019	2018	\$ Change	% Change
United States	\$ 311.9	\$ 290.5	\$ 21.4	7.4%
Europe	386.9	417.4	(30.5)	(7.3%)
Rest of World	236.2	237.9	(1.7)	(0.7%)

A reconciliation of reported net sales to non-US GAAP net sales, excluding precious metal content, by geographic region is as follows:

(in millions)	Three Months Ended March 31, 2019			
	United States	Europe	Rest of World	Total
Net sales	\$ 313.4	\$ 395.8	\$ 237.0	\$ 946.2
Less: precious metal content of sales	1.5	8.9	0.8	11.2
Net sales, excluding precious metal content	\$ 311.9	\$ 386.9	\$ 236.2	\$ 935.0

(in millions)	Three Months Ended March 31, 2018			
	United States	Europe	Rest of World	Total
Net sales	\$ 291.8	\$ 425.5	\$ 238.8	\$ 956.1
Less: precious metal content of sales	1.3	8.1	0.9	10.3

Net sales, excluding precious metal content	\$ 290.5	\$ 417.4	\$ 237.9	\$ 945.8
---	----------	----------	----------	----------

### United States

Reported net sales increased by 7.4% in the quarter ended March 31, 2019 as compared to the quarter ended March 31, 2018. Net sales, excluding precious metal content, increased by 7.4% during the first quarter of 2019 as compared to the first quarter of 2018. During the three months ended March 31, 2019, Consumables sales were negatively impacted by one less selling day as compared to the three months ended March 31, 2018. Based on the Company's estimate, inventory held by certain distributors decreased by approximately \$6 million during the three months ended March 31, 2018.

For the three month period ended March 31, 2019, net sales, excluding precious metal content, increased 7.5% on a constant currency basis. This includes a benefit of 1.5% from acquisitions and an unfavorable impact from discontinued products of 40 basis points, which results in internal sales growth of 6.4%. The internal sales growth was attributable to the Technologies & Equipment segment.

### Europe

Reported net sales decreased by 7.0% during the quarter ended March 31, 2019 as compared to the quarter ended March 31, 2018. Net sales, excluding precious metal content, decreased by 7.3% in the first quarter of 2019 as compared to the first quarter of 2018, which was negatively impacted by approximately 6.7% due to the strengthening of the U.S. dollar as compared to the prior year period. Reported net sales in the three months ended March 31, 2019 were negatively impacted in this region by the purchasing behavior ahead of a biennial trade show as compared to the three months ended March 31, 2018.

For the three month period ended March 31, 2019, net sales, excluding precious metal content, decreased 60 basis points on a constant currency basis. This includes a benefit of 10 basis points from acquisitions and an unfavorable impact from discontinued products of 60 basis points, resulting in negative internal sales growth of 10 basis points. The decline in internal sales growth was driven primarily by the Consumables segment, mostly offset by internal sales growth in the Technologies and Equipment segment.

### Rest of World

Reported net sales decreased by 0.8% in the quarter ended March 31, 2019 as compared to the quarter ended March 31, 2018. Net sales, excluding precious metal content, decreased 0.7% in the first quarter of 2019 as compared to the first quarter of 2018. The first quarter of 2019 was negatively impacted by approximately 7.0% due to the strengthening of the U.S. dollar as compared to the same prior year period.

For the three month period ended March 31, 2019, sales, excluding precious metal content, increased 6.3% on a constant currency basis. This includes a benefit of 40 basis points from acquisitions and an unfavorable impact from discontinued products of 2.2%, which results in internal sales growth of 8.1%. The internal sales growth was driven by the Technologies & Equipment segment.

### **Gross Profit**

	Three Months Ended			
	March 31,			
(in millions)	2019	2018	\$ Change	% Change
Gross profit	\$ 499.7	\$ 514.1	\$ (14.4)	(2.8%)
Gross profit as a percentage of net sales, including precious metal content	52.8%	53.8%		
Gross profit as a percentage of net sales, excluding precious metal content	53.4%	54.4%		

Gross profit as a percentage of net sales, excluding precious metal content, decreased by 100 basis points for the quarter ended March 31, 2019 as compared to the same three month period ended March 31, 2018.

For the three months ended March 31, 2019, the decrease in the gross profit rate was primarily driven by the expense related to the divestiture of non-strategic businesses and higher manufacturing and distribution costs, partially offset by cost savings initiatives as compared to the three months ended March 31, 2018.

**Operating Expenses**

(in millions)	Three Months Ended		\$ Change	% Change
	2019	2018		
Selling, general and administrative expenses ("SG&A")	\$ 431.9	\$ 435.2	\$ (3.3)	(0.8%)
Restructuring and other costs	20.5	10.2	10.3	NM
SG&A as a percentage of net sales, including precious metal content	45.6%	45.5%		
SG&A as a percentage of net sales, excluding precious metal content	46.2%	46.0%		

NM - Not meaningful

**SG&A Expense**

SG&A expenses, including research and development expenses, as a percentage of net sales, excluding precious metal content, for the quarter ended March 31, 2019 increased 20 basis points as compared to the quarter ended March 31, 2018.

For the three months ended March 31, 2019, the higher rate was driven primarily by expenses related to the divestiture of non-strategic businesses which impacted the rate by approximately 150 basis points, biennial trade show expenses and the unfavorable impact of foreign currency which together impacted the rate by approximately 130 basis points. These unfavorable impacts were mostly offset by favorable operating leverage which impacted the rate by approximately 180 basis points and favorable net reorganization activities which impacted the rate by approximately 75 basis points as compared to the three months ended March 31, 2018.

#### Restructuring and Other Cost

The Company recorded restructuring and other costs of \$20.5 million for the three months ended March 31, 2019 compared to \$10.2 million for the three months ended March 31, 2018.

The Company recorded \$14.2 and \$7.4 million in restructuring costs during the three months ended March 31, 2019 and March 31, 2018, respectively.

During the three months ended March 31, 2019, the Company recorded \$6.3 million of other costs which consist primarily of impairment charges of \$5.3 million related to indefinite-lived intangible assets. During the three months ended March 31, 2018, the Company recorded \$2.8 million in other costs mostly related to legal settlements.

#### **Other Income and Expense**

(in millions)	Three Months Ended March 31,		Change
	2019	2018	
Net interest expense	\$ 7.3	\$ 8.0	\$ (0.7)
Other expense (income), net	(13.8)	(34.1)	20.3
Net interest and other expense	\$ (6.5)	\$ (26.1)	\$ 19.6

#### Net Interest Expense

Net interest expense for the three months ended March 31, 2019 decreased \$0.7 million as compared to the three months ended March 31, 2018. Lower average debt level in 2019 was partially offset by higher average US dollar variable interest rates when compared to the prior year period resulting in lower net interest expense.

#### Other Expense (Income), Net

Other expense (income), net for the three months ended March 31, 2019 was income of \$13.8 million, comprised primarily of a gain on the sale of a non-strategic business. Other expense (income), net for the three months ended March 31, 2018 was income of \$34.1 million, comprised primarily of a gain recorded on the sale of marketable securities.

**Income Taxes and Net Income**

	Three Months Ended March 31,		
(in millions, except per share data)	2019	2018	\$ Change
Provision for income taxes	\$ 14.6	\$ 13.7	\$ 0.9
Effective income tax rate	27.4%	14.5%	
Net income attributable to Dentsply Sirona	\$ 39.2	\$ 81.2	\$ (42.0)
Net income per common share - diluted	\$ 0.17	\$ 0.35	

**Provision for Income Taxes**

For the three months ended March 31, 2019, income taxes were a provision of \$14.6 million as compared to a provision of \$13.7 million in the quarter ended March 31, 2018.

During the quarter ended March 31, 2019, the Company recorded \$2.4 million of tax expense for discrete tax matters. The Company also recorded a \$1.5 million tax benefit related to the indefinite-lived intangible asset impairment charge recorded during the quarter. Excluding these discrete tax items and adjusting pretax income to exclude the pretax charge related to the impairment of the indefinite-lived intangible assets, the Company's effective tax rate was 23.2%.

The Company has outlined its global business improvement plans which, upon realization of the benefits of these plans, could give rise to the release of a valuation allowance that has been established on the Company's deferred tax assets, in a future period.

For the first quarter of 2018, the Company recorded the following discrete tax items, \$2.2 million of excess tax benefit related to employee share-based compensation, tax expense of \$1.2 million related to valuation allowances, \$0.2 million of tax expense related to enacted statutory rate changes, \$7.2 million of tax expense for other discrete tax matters and \$3.4 million tax benefit related to U.S. tax reform. The Company also recorded \$1.1 million of tax expense as a discrete item related to the gain on sale of marketable securities. Excluding these discrete tax items and adjusting pretax income for the gain on the sale of marketable securities, net of tax, the Company's effective tax rate was 18.9%.

The Company's effective income tax rate for the first quarter of 2019 included the net impact of amortization of purchased intangible assets, restructuring program related costs and other costs, business combination related costs, credit risk and fair value adjustments, and income tax related adjustments which impacted income before income taxes and the provision for income taxes by \$90.7 million and \$20.1 million, respectively.

The Company's effective income tax rate for the first quarter of 2018 included the net impact of amortization of purchased intangible assets, restructuring program related costs and other costs, credit risk and fair value adjustments, business combination related costs, income tax related adjustments and the gain on sale of marketable securities, which impacted income before income taxes and the provision for income taxes by \$35.7 million and \$14.2 million, respectively.

#### Net Income attributable to Dentsply Sirona

In addition to the results reported in accordance with US GAAP, the Company provides adjusted net income attributable to Dentsply Sirona and adjusted earnings per diluted common share ("adjusted EPS"). The Company discloses adjusted net income attributable to Dentsply Sirona to allow investors to evaluate the performance of the Company's operations exclusive of certain items that impact the comparability of results from period to period and may not be indicative of past or future performance of the normal operations of the Company and certain large non-cash charges related to intangible assets either purchased or acquired through a business combination. The Company believes that this information is helpful in understanding underlying operating trends and cash flow generation.

Adjusted net income and adjusted EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes adjusted net income and adjusted EPS and the performance of the Company is measured on this basis along with other performance metrics.

The adjusted net income attributable to Dentsply Sirona consists of net income attributable to Dentsply Sirona adjusted to exclude the following:

(1) *Business combination related costs and fair value adjustments.* These adjustments include costs related to integrating and consummating mergers and recently acquired businesses, as well as costs, gains and losses related to the disposal of businesses or significant product lines. In addition, this category includes the roll off to the

consolidated statement of operations of fair value adjustments related to business combinations, except for amortization expense noted below. These items are irregular in timing and as such may not be indicative of past and future performance of the Company and are therefore excluded to allow investors to better understand underlying operating trends.

(2) *Restructuring program related costs and other costs.* These adjustments include costs related to the implementation of restructuring initiatives as well as certain other costs. These costs can include, but are not limited to, severance costs, facility closure costs, lease and contract terminations costs, related professional service costs, duplicate facility and labor costs associated with specific restructuring initiatives, as well as, legal settlements and impairments of assets. These items are irregular in timing, amount and impact to the Company's financial performance. As such, these items may not be indicative of past and future performance of the Company and are therefore excluded for the purpose of understanding underlying operating trends.

(3) *Amortization of purchased intangible assets.* This adjustment excludes the periodic amortization expense related to purchased intangible assets. Amortization expense has been excluded from adjusted net income attributed to Dentsply Sirona to allow investors to evaluate and understand operating trends excluding these large non-cash charges.

(4) *Credit risk and fair value adjustments.* These adjustments include both the cost and income impacts of adjustments in certain assets and liabilities including the Company's pension obligations, that are recorded through net income which are due solely to the changes in fair value and credit risk. These items can be variable and driven more by market conditions than the Company's operating performance. As such, these items may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

(5) *Gain on sale of marketable securities.* This adjustment represents the gain on the sale of marketable securities held by the Company. The gain has been excluded from adjusted net income attributed to Dentsply Sirona to allow investors to evaluate and understand operating trends excluding this gain.

(6) *Income tax related adjustments.* These adjustments include both income tax expenses and income tax benefits that are representative of income tax adjustments mostly related to prior periods, as well as the final settlement of income tax audits, and discrete tax items resulting from the implementation of restructuring initiatives and the vesting and exercise of employee share-based compensation. These adjustments are irregular in timing and amount and may significantly impact the Company's operating performance. As such, these items may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

Adjusted earnings per diluted common share is calculated by dividing adjusted net income attributable to Dentsply Sirona by diluted weighted-average common shares outstanding. Adjusted net income attributable to Dentsply Sirona and adjusted earnings per diluted common share are considered measures not calculated in accordance with US GAAP, and therefore are non-US GAAP measures. These non-US GAAP measures may differ from other companies. Income tax related adjustments may include the impact to adjust the interim effective income tax rate to the expected annual effective tax rate. The non-US GAAP financial information should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

Three Months Ended

March 31, 2019

(in millions, except per share amounts)	Net Income	Per Diluted Common Share
Net income attributable to Dentsply Sirona	\$ 39.2	\$ 0.17
Pre-tax non-US GAAP adjustments:		
Amortization of		

purchased  
intangible  
assets

Restructuring

program  
related  
costs

38.9  
and  
other  
costs

Business  
combination

related  
costs  
and

2.3  
fair  
value  
adjustments

Credit  
risk

and  
fair

1.3  
value  
adjustments

Tax  
impact  
of

the  
pre-

(22.6)  
non-US  
GAAP  
adjustments

(a)

Subtotal

non-US  
GAAP

adjustments

0.31

Income

tax  
related

adjustments

0.01

Adjusted

non-US

GAAP

net

income

109.8

\$

0.49

(a) The tax amount was calculated using the applicable statutory tax rate in the tax jurisdiction where the non-US GAAP adjustments were

generated.

43

---

Three Months Ended

March 31, 2018

(in millions, except per share amounts)

Net Income	Per Diluted Common Share
Net income attributable to Dentsply Sirona	0.35
Pre-tax non-US GAAP adjustments:	
Amortization of purchased intangible assets	
Restructuring program related costs and other costs	
Credit risk and fair value adjustments	
Business combination related costs and fair value adjustments	
Gain on sale	

of  
marketable  
securities

Tax  
impact

of  
the  
pre-tax

(22.9)  
non-US  
GAAP  
adjustments

(a)

Subtotal

non-US  
GAAP

adjustments

12.8  
0.06

Income

tax  
related

adjustments

8.7  
0.04

Adjusted

non-US

GAAP 102.7 \$ 0.45

net

income

(a) The tax amount was calculated using the applicable statutory tax rate in the tax jurisdiction where the non-US GAAP adjustments were generated.

### Adjusted Operating Income and Margin

Adjusted operating income and margin is another important internal measure for the Company. Operating income in accordance with US GAAP is adjusted for the items noted above which are excluded on a pre-tax basis to arrive at adjusted operating income, a non-US GAAP measure. The adjusted operating margin is calculated by dividing adjusted operating income by net sales, excluding precious metal content.

Senior management receives a monthly analysis of operating results that includes adjusted operating income. The performance of the Company is measured on this basis along with the adjusted non-US GAAP earnings noted above as well as other performance metrics. This non-US GAAP measure may differ from other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

	Three Months Ended	
	March 31, 2019	
(in millions)	Operating Income	Percentage of Net Sales,

		Excluding Precious Metal Content
Operating Income	\$ 47.3	5.1%
Amortization of purchased intangible assets	48.2	5.2%
Restructuring program related costs and other costs	47.9	5.1%
Business combination related costs and fair value adjustments	2.1	0.2%
Adjusted non-US GAAP Operating Income	\$ 145.5	15.6%

(in millions)	Three Months Ended March 31, 2018	
	Operating Income	Percentage of Net Sales, Excluding Precious Metal Content
Operating Income	\$ 68.7	7.3%
Amortization of purchased intangible assets	50.0	5.3%
Restructuring program related costs and other costs	15.9	1.6%
Business combination related costs and fair value adjustments	3.0	0.3%
Adjusted non-US GAAP Operating Income	\$ 137.6	14.5%

### Operating Segment Results

#### Third Party Net Sales, Excluding Precious Metal Content

(in millions)	Three Months Ended March 31,			
	2019	2018	\$ Change	% Change
Technologies & Equipment	\$ 520.8	\$ 510.1	\$ 10.7	2.1%
Consumables	414.2	435.7	(21.5)	(4.9%)

#### Segment Operating Income

Three Months Ended  
March 31,

Edgar Filing: DENTSPLY SIRONA Inc. - Form 10-Q

(in millions)	2019	2018	\$ Change	% Change
Technologies & Equipment	\$ 71.8	\$ 68.5	\$ 3.3	4.8%
Consumables	105.7	114.7	(9.0)	(7.8%)

A reconciliation of reported net sales to non-US GAAP net sales, excluding precious metal content, by segment is as follows:

(in millions)	Three Months Ended		
	March 31, 2019		
	Technologies & Equipment	Consumables	Total
Net sales	\$ 520.8	\$ 425.4	\$ 946.2
Less: precious metal content of sales	—	11.2	11.2
Net sales, excluding precious metal content	\$ 520.8	\$ 414.2	\$ 935.0

(in millions)	Three Months Ended March 31, 2018		
	Technologies & Equipment	Consumables	Total
Net sales	\$ 510.1	\$ 446.0	\$ 956.1
Less: precious metal content of sales	—	10.3	10.3
Net sales, excluding precious metal content	\$ 510.1	\$ 435.7	\$ 945.8

### Technologies & Equipment

Reported net sales increased by 2.1% in the quarter ended March 31, 2019 as compared to the quarter ended March 31, 2018. Net sales, excluding precious metal content, increased by 2.1% in the first quarter of 2019 as compared to the first quarter of 2018. Net sales, excluding precious metal content, were negatively impacted by approximately 5.1% due to the strengthening of the U.S. dollar over the prior year period. The first quarter of 2019 benefited from new product sales. Based on the Company's estimate, inventory held by certain distributors decreased by approximately \$8 million during the three months ended March 31, 2018.

For the three months ended March 31, 2019, net sales, excluding precious metal content, increased 7.2% on a constant currency basis compared to the three months ended March 31, 2018. This includes a benefit of 1.0% related to acquisitions and an unfavorable impact from discontinued products of 1.7%, which results in internal sales growth of 7.9%. All geographic regions experienced internal sales growth.

The operating income increased \$3.3 million or 4.8% for the three months ended March 31, 2019 as compared to the same three month period in 2018. The increase in operating income was related to an increase in net sales as well as favorable product mix.

### Consumables

Reported net sales decreased by 4.6% in the quarter ended March 31, 2019 as compared to the quarter ended March 31, 2018. Net sales, excluding precious metal content, decreased 4.9% for the three months ended March 31, 2019 as compared to the three months ended March 31, 2018. Net sales, excluding precious metal content, were negatively impacted by approximately 4.3% due to the strengthening of the U.S. dollar over the same prior year period. Reported net sales in the three months ended March 31, 2019 were negatively impacted by one less selling day in the U.S. region as compared to the three months ended March 31, 2018.

For the three month period ended March 31, 2019, net sales, excluding precious metal content, decreased 0.6% on a constant currency and internal sales growth basis. The negative internal sales growth was driven by the U.S. and Europe regions, partially offset by the Rest of World region.

The operating income decreased \$9.0 million or 7.8% for the three months ended March 31, 2019 as compared to the same three month period in 2018. The decrease in operating income was related to a decrease in net sales and increased manufacturing and distribution costs.

### **CRITICAL ACCOUNTING POLICIES**

Except as noted below, there have been no other significant material changes to the critical accounting policies as disclosed in the Company's Form 10-K for the year ended December 31, 2018.

#### **Annual Goodwill Impairment Testing**

##### Goodwill

Goodwill is not amortized; instead, it is tested for impairment annually or more frequently if indicators of impairment exist or if a decision is made to sell a business. The valuation date for annual impairment testing is April 30.

At March 31, 2019, the Company noted no impairment triggering events related to the Company's reporting units. Should the Company's analysis in the future indicate an increase in discount rates or a degradation in the overall markets served by these reporting units, it could result in impairment of the carrying value of goodwill to its implied fair value. There can be no assurance that the Company's future goodwill impairment testing will not result in a charge to earnings.

#### Indefinite-Lived Assets

Indefinite-lived intangible assets consist of tradenames and trademarks and are not subject to amortization; instead, they are tested for impairment annually or more frequently if indicators of impairment exist or if a decision is made to sell a business. The valuation date for annual impairment testing is April 30.

During the three months ended March 31, 2019, the Company impaired \$5.3 million of product tradenames and trademarks related to the Technologies & Equipment segment. The impairment was the result of a change in forecasted sales related to divestitures of non-strategic product lines.

Should the Company's analysis in the future indicate an increase in discount rates or a degradation in the use of the tradenames and/or trademarks, it could result in impairment of the carrying value of the indefinite-lived assets to its implied fair value. There can be no assurance that the Company's future indefinite-lived asset impairment testing will not result in a charge to earnings.

### **LIQUIDITY AND CAPITAL RESOURCES**

#### **Three months ended March 31, 2019**

Net income of \$39.2 million for the three months ended March 31, 2019, decreased \$41.9 million as compared to net income of \$81.1 million for the three months ended March 31, 2018, primarily due to the prior year non-cash gain on sale of equity security. Cash flow from operating activities during the three months ended March 31, 2019 was \$29.3 million compared to \$55.1 million during the three months ended March 31, 2018. Cash from operations decreased \$25.8 million for the first three months of 2019 as compared to the same period in 2018 and was primarily due to restructuring and legal settlement payments and lower cash from receivables as compared to prior year. The Company's cash and cash equivalents decreased by \$84.2 million to \$225.4 million during the three months ended March 31, 2019.

For the three months ended March 31, 2019, on a constant currency basis, the number of days of sales outstanding in accounts receivable increased by 4 days to 63 days as compared to 59 days at December 31, 2018. On a constant currency basis, the number of days of sales in inventory increased by 4 days to 128 days at March 31, 2019 as compared to 124 days at December 31, 2018.

Cash used in investing activities during the first three months of 2019 included capital expenditures of \$33.9 million. The Company expects capital expenditures to be in the range of approximately \$165 million to \$175 million for the full year 2019.

Cash used in financing activities for the three months ended March 31, 2019 was primarily related to dividend payments of \$19.5 million, payments of short term borrowings of \$67.9 million and cash proceeds from an early termination of a net investment hedge of \$17.4 million.

The Company has authorization to maintain up to \$1.0 billion of treasury stock under its stock repurchase program. Additional share repurchases, if any, will be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions or other transactions in such amounts and at such times as the

Company deems appropriate based upon prevailing market and business conditions and other factors. There were no share repurchases during the three months ended March 31, 2019. At March 31, 2019, the Company held 40.7 million shares of treasury stock. The Company received proceeds of \$19.8 million as a result of the exercise of 0.5 million of stock options during the three months ended March 31, 2019.

The Company's total borrowings decreased by a net \$91.5 million during the three months ended March 31, 2019, which includes a decrease of \$20.4 million due to exchange rate fluctuations on debt denominated in foreign currencies. At March 31, 2019 and December 31, 2018, the Company's ratio of total net debt to total capitalization was 20.8%. The Company defines net debt as total debt, including current and long-term portions, less cash and cash equivalents and total capitalization as the sum of net debt plus equity.

The Company is obligated to pay annual principal amortization of \$8.8 million representing a 5% mandatory principal amortization due in each of the first six years under the terms of the PNC Term Loan with a final maturity of August 25, 2020. The sixth annual installment in the amount of \$8.8 million will be due in August 2019 and has been classified as current in the Consolidated Balance Sheets.

Under its multicurrency revolving credit agreement, the Company is able to borrow up to \$700.0 million through July 27, 2023. The facility is unsecured and contains certain affirmative and negative covenants relating to the operations and financial condition of the Company. The most restrictive of these covenants pertain to asset dispositions and prescribed ratios of indebtedness to total capital and operating income, plus depreciation and amortization to interest expense. At March 31, 2019, the Company was in compliance with these covenants. The Company also has available an aggregate \$500.0 million under a U.S. dollar commercial paper facility. The revolver serves as a back-up to the commercial paper facility, thus the total available credit under the commercial paper facility and the multi-currency revolving credit facilities in the aggregate is \$700.0 million. At March 31, 2019, there were no outstanding borrowings under the previous \$500.0 million multi-currency revolving credit facility. The Company had no borrowings under the Commercial Paper facility at March 31, 2019.

The Company also has access to \$31.6 million in uncommitted short-term financing under lines of credit from various financial institutions. The lines of credit have no major restrictions and are provided under demand notes between the Company and the lending institutions. At March 31, 2019, the Company had \$11.7 million outstanding under these short-term lines of credit. At March 31, 2019, the Company had total unused lines of credit related to the revolving credit agreement and the uncommitted short-term lines of credit of \$719.9 million.

At March 31, 2019, the Company held \$44.8 million of precious metals on consignment from several financial institutions. The consignment agreements allow the Company to acquire the precious metal at market rates at a point in time which is approximately the same time and for the same price as alloys are sold to the Company's customers. In the event that the financial institutions would discontinue offering these consignment arrangements, and if the Company could not obtain other comparable arrangements, the Company may be required to obtain third party financing to fund an ownership position in the required precious metal inventory levels.

As a result of U.S. tax reform, \$271.7 million of cash and cash equivalents held by the Company's non-U.S. subsidiaries was subject to current tax in the U.S. in 2018. At March 31, 2019 the Company had repatriated \$106.7 of the \$271.7 million that was taxable under the Act. However, to the extent the Company repatriates these funds to the U.S., the Company will be required to pay income taxes in certain U.S. states and applicable foreign withholding taxes on those amounts during the period when such repatriation occurs.

Except as stated above, there have been no material changes to the Company's scheduled contractual cash obligations disclosed in its Form 10-K for the year ended December 31, 2018.

The Company continues to review its debt portfolio and may refinance additional debt in the near-term as interest rates remain at historically low levels.

## **NEW ACCOUNTING PRONOUNCEMENTS**

Refer to Part 1, Item 1, Note 1, Significant Accounting Policies, to the Unaudited Interim Consolidated Financial Statements of this Form 10-Q for a discussion of recent accounting standards and pronouncements.

### **Item 3 – Quantitative and Qualitative Disclosures about Market Risk**

There have been no significant material changes to the market risks as disclosed in the Company's Form 10-K for the year ended December 31, 2018.

### **Item 4 – Controls and Procedures**

#### Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

The Company's management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that it is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

#### Changes in Internal Control Over Financial Reporting

There have been no changes in the Company's internal controls over financial reporting that occurred during the quarter ended March 31, 2019, that have materially affected, or are likely to materially affect, its internal control over financial reporting.

## **PART II – OTHER INFORMATION**

### **Item 1 – Legal Proceedings**

Reference to Part I, Item 1, Note 15 Commitments and Contingencies, in the Notes to Unaudited Interim Consolidated Financial Statements of this Form 10-Q.

### **Item 1A – Risk Factors**

There have been no significant material changes to the risk factors as disclosed in Part 1A, “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2018.

### **Item 2 – Unregistered Sales of Securities and Use of Proceeds**

#### Issuer Purchases of Equity Securities

During the quarter ended March 31, 2019, the Company had no repurchases of common shares under the stock repurchase program.

**Item 6 – Exhibits**

<u>Exhibit Number</u>	<u>Description</u>
<u>10.1</u>	Non-Employee Director Compensation Policy, dated March 27, 2019
<u>31.1</u>	Section 302 Certification Statement Chief Executive Officer
<u>31.2</u>	Section 302 Certification Statement Chief Financial Officer
<u>32</u>	Section 906 Certification Statements
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL

Taxonomy  
Extension  
Definition  
Linkbase  
Document  
XBRL  
101.LAB Extension  
Labels Linkbase  
Document  
XBRL  
101.PRE Taxonomy  
Extension  
Presentation  
Linkbase  
Document

